🔗 Share this article

As the United States proceeds with historic adjustments to its vaccination schedules, a particular individual has emerged in a surprising turn: Høeg, a US-based sports medicine doctor and epidemiologist who rose to prominence by questioning COVID-19 vaccinations throughout the pandemic and has concentrated on alleged deaths following COVID-19 vaccination in her short time at the Food and Drug Administration.

Scheduled Changes to Childhood Vaccine Program

Health officials had intended to announce major changes to the pediatric immunization program earlier this month, bringing the US with the Danish national calendar, it is understood – a major change that would place the US at odds with a large portion of the international standard with no evidence for improved outcomes. This reveal has been delayed until the coming year.

Instead of Vinay Prasad, Tracy Beth Høeg is set to present at the meeting. She was just designated acting director of the FDA’s drug evaluation center, the fifth person to run the office this year.

Consolidating Power at the FDA

The acting appointment may indicate a closer partnership between the drug and vaccine divisions as Dr. Høeg and Dr. Prasad consolidate power at the agency – and it suggests a increased emphasis upon reevaluating previously authorized vaccines at the FDA.

The new acting director has repeatedly called for discontinuing specific pediatric shot schedules in the US in order to be more like Denmark, a country with nationalized medicine and a population approximately the size of the state of Wisconsin.

So far public appearances, she has kept her attention on vaccines – traditionally the responsibility of Prasad, chief of the FDA’s vaccine center – instead of medication approval.

Doubts Over Qualifications

The appointee has no apparent background in drug development, regulation or administrative roles, which has been customary for former directors of the biologics center. She has worked at the FDA as a top consultant to the agency head and the vaccine center since earlier this year.

“She doesn’t seem to have any of the qualifications” for running the drug-regulation department, said Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She has no expertise in running a sizeable institution. She is not an expert in pharmaceutical oversight.”

Past directors of CBER would “grasp regulatory frameworks and the underlying principles of pharmaceutical innovation”, commented Janet Woodcock. “Objectively, she lacks the type of experience that previous people who led CBER have had.”

This division has an immense portfolio at the agency, the former commissioner emphasized.

“The public just pays attention on the novel medication approvals, but the generic program clears numerous off-brand pharmaceuticals. There is also a biosimilars program, over-the-counter program and other areas, and all of those need to be managed,” Dr. Woodcock noted. “The responsibility you overlook, that is precisely what that I always told people is going to cause problems.”

There is also, a significant administrative aspect to the role, which manages more than 5,000 personnel. “It is a enormous administrative position, if you execute it properly,” Woodcock said.

Official Statement and Contentious Policies

Regarding questions about Høeg’s qualifications and whether this selection represents more teamwork among FDA leaders on immunizations, a spokesperson responded that the “concerns are based on inaccurate presumptions”.

“This background matches the functions of her position,” the official said, pointing to the period Høeg spent counseling the FDA commissioner on “drug safety and regulatory science, including computerized risk analysis and shot safety tracking”.

As the temporary head, Høeg takes over the commissioner’s controversial expedited review system, a contentious rapid drug-approval program that apparently worried her preceding directors. “How are these therapies being selected for this expedited pathway? Who is making the decisions?” Howard asked. “There is a lot of confidentiality happening at the FDA right now.”

In general, he said, “the FDA looks to be trending towards laxer oversight of all drugs, except for immunizations.”

Documented Track Record on Immunizations

Concerning vaccines, Høeg has a more established, if troubling, past, critics said. She authored a analysis using unconfirmed crowd-sourced reports to determine the incidence of myocarditis following Covid immunization. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have changed statistics to suggest COVID-19 vaccines are pose a greater threat than they are.

Included in her “desired changes” for the current federal leadership included revising guidelines for new vaccines and discontinuing “non-essential” vaccines, she remarked post-election on a audio program. At the FDA, Høeg has according to sources floated the idea of barring adolescent males from receiving Covid vaccinations.

“She is an complete true believer who starts off with her beliefs and tailors the evidence to accommodate the data in a highly deceptive, dishonest manner,” Dr. Howard said.

Taking Control and a “Campaign of Retribution”

Høeg became part of fellow dissenters, {like|